Xeris Pharmaceuticals (NASDAQ:XERS) announced its quarterly earnings data on Thursday. The company reported ($1.22) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.01, Fidelity Earnings reports. Xeris Pharmaceuticals had a negative return on equity of 107.65% and a negative net margin of 4,876.50%. The business had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.20 million.
NASDAQ:XERS opened at $8.02 on Friday. The stock’s fifty day moving average price is $8.71 and its two-hundred day moving average price is $10.49. Xeris Pharmaceuticals has a 1 year low of $6.85 and a 1 year high of $25.49. The company has a market cap of $236.68 million, a P/E ratio of -1.61 and a beta of -0.49. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.00 and a quick ratio of 6.00.
Several equities analysts have weighed in on XERS shares. Zacks Investment Research lowered Xeris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Royal Bank of Canada set a $18.00 target price on Xeris Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 7th. ValuEngine downgraded Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, September 30th. Finally, Mizuho restated a “buy” rating and set a $22.00 target price on shares of Xeris Pharmaceuticals in a research report on Friday.
In other news, insider Steven Prestrelski sold 27,700 shares of the firm’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $9.00, for a total transaction of $249,300.00. 7.43% of the stock is currently owned by company insiders.
Xeris Pharmaceuticals Company Profile
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Further Reading: Diversification Important in Investing
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.